Unknown

Dataset Information

0

Do cerebrospinal fluid transfer methods affect measured amyloid ?42, total tau, and phosphorylated tau in clinical practice?


ABSTRACT: INTRODUCTION:Cerebrospinal fluid (CSF) neurodegenerative markers are measured clinically to support a diagnosis of Alzheimer's disease. Several preanalytical factors may alter the CSF concentrations of amyloid ? 1-42 (A?1-42) in particular with the potential to influence diagnosis. We aimed to determine whether routine handling of samples alters measured biomarker concentration compared with that of prompt delivery to the laboratory. METHODS:Forty individuals with suspected neurodegenerative diseases underwent diagnostic lumbar punctures using a standardized technique. A sample of each patient's CSF was sent to the laboratory by four different delivery methods: (1) by courier at room temperature; (2) by courier, on ice; (3) using standard hospital portering; and (4) after quarantining for >24 hours. A?1-42, total tau (t-tau), and phosphorylated tau (p-tau) levels measured using standard enzyme-linked immunosorbent assay techniques were compared between transfer methods. RESULTS:There were no significant differences in A?1-42, t-tau, or p-tau concentrations measured in samples transported via the different delivery methods despite significant differences in time taken to deliver samples. DISCUSSION:When CSF is collected in appropriate tubes, transferred at room temperature, and processed within 24 hours, neurodegenerative markers can be reliably determined.

SUBMITTER: Paterson RW 

PROVIDER: S-EPMC4877931 | biostudies-literature | 2015 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

Do cerebrospinal fluid transfer methods affect measured amyloid β42, total tau, and phosphorylated tau in clinical practice?

Paterson Ross W RW   Toombs Jamie J   Chapman Miles D MD   Nicholas Jennifer M JM   Heslegrave Amanda J AJ   Slattery Catherine F CF   Foulkes Alexander J M AJ   Clark Camilla N CN   Lane Christopher A S CA   Weston Philip S J PS   Lunn Michael P MP   Fox Nick C NC   Zetterberg Henrik H   Schott Jonathan M JM  

Alzheimer's & dementia (Amsterdam, Netherlands) 20150702 3


<h4>Introduction</h4>Cerebrospinal fluid (CSF) neurodegenerative markers are measured clinically to support a diagnosis of Alzheimer's disease. Several preanalytical factors may alter the CSF concentrations of amyloid β 1-42 (Aβ1-42) in particular with the potential to influence diagnosis. We aimed to determine whether routine handling of samples alters measured biomarker concentration compared with that of prompt delivery to the laboratory.<h4>Methods</h4>Forty individuals with suspected neurod  ...[more]

Similar Datasets

| S-EPMC3353832 | biostudies-other
| S-EPMC6218126 | biostudies-literature
| S-EPMC10466826 | biostudies-literature
| S-EPMC6052894 | biostudies-literature
| S-EPMC3836828 | biostudies-literature
| S-EPMC6114488 | biostudies-literature
| S-EPMC5538341 | biostudies-other
| S-EPMC10470314 | biostudies-literature
| S-EPMC3466497 | biostudies-literature
| S-EPMC6991202 | biostudies-literature